Menu
  • The inaugural US E-Cigarette Summit was held in Washington DC, on Monday May 8, 2017 and welcomed over 250 people
  • The 2nd Annual US E-Cigarette Summit will take place April 30, 2018......Registration is now open

Science, Regulation and Public Health

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life.  Despite decades of successful tobacco control efforts, we are still a long way from ending the smoking epidemic.

The emergence of e-cigarettes, which deliver nicotine but without the vast range of carcinogens and toxins found in combustible tobacco products has created one of the most controversial and contentious public health issues of a generation, with divisions appearing within longstanding professional alliances in both Tobacco Control and Public Health communities, despite a continued shared goal of protecting public health and ending the smoking epidemic.

The E-Cigarette Summit provides a  neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.

2017 Key Topics include:

  • How safe are e-cigarettes – current clinical trials – what do we know and what do we still need to find out
  • Do e-cigarettes undermine current tobacco control measures or offer new opportunities
  • Evidence on Gateway and current use, what is the available data and how should it be interpreted.
  • Use of e-cigarettes in public what are the concerns
  • How will regulation affect the current market and products available. Intended and unintended consequences
  • Advertising and promotion, what are the issues and how should these be addressed
  • Conflicting interests that arise from the dual corporate ownership of tobacco products and harm reduction products
  • What should cessation practitioners be saying to current smokers?

Confirmed Speakers/Panel Presenters

Thomas J. Glynn, PhD – Consulting Professor, Stanford Prevention Research Center, Stanford University School of Medicine

Prof Ken Warner – Professor, Health Management & Policy, School of Public Health, University of Michigan

Andrea C. Villanti – Director Regulatory Science & Policy, Schroeder Institute for Tobacco Research and Policy Studies.

Prof Linda Bauld – Professor of Health Policy, University of Stirling, Cancer Research UK and UKCTAS

Robin J. Mermelstein, PhD – Professor of Psychology and Director Institute for Health Research and Policy ( IHRP), University of Illinois, Chicago

Raymond Niaura, Ph.D – Director of Science at the Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative

Judith J. Prochaska, PhD, MPH – Associate Professor of Medicine (Stanford Prevention Research Center)

Prof Neal Benowitz – Professor of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco, USA

Prof. Jonathon Foulds – Professor of Public Health Sciences and Psychiatry, Penn State Tobacco Center of Regulatory Science , Cancer Institute

Dr Konstantinos Farsalinos – Researcher, Onassis Cardiac Surgery Center Greece, University of Patras, Greece

Joanna Cohen – Professor of Disease Prevention and the Director of the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health

Matthew L. Myers – President, Campaign for Tobacco-Free Kids

Deborah Arnott – Chief Executive, Action on Smoking & Health (ASH), UK

Kevin Walton, PhD – Chief, Clinical Research Grants Branch, Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, NIH

David Graham – President and Managing Partner, Reveritas Group

Eric N. Lindblom JD – Director for Tobacco Control and Food and Drug Law at the O’Neill Institute for National and Global Health Law

Prof Ann McNeill – Professor of Tobacco Addiction – UK Centre for Tobacco and Alcohol Studies (UKCTAS) Kings College London

Dr. James Davis – Medical Director, Duke Center for Smoking Cessation, Assistant Professor of Medicine

Prof Dorothy Hatsukami – Professor, Department of Psychiatry, Associate Director of Cancer Prevention and Control for the Masonic Cancer Center, University of Minnesota

AG Tom Miller –The Attorney General of Iowa